This study investigates alternatives to current financial accounting treatment of research and development 
tures in the period incurred, provides a strong incentive to decrease R&D, because expensed R&D has an immediate adverse impact on reported profits. International business firms do not suffer under this impact which may effect the relevancy of financial earnings (Barth and Clinch, 1998; Carnegie and Turner, 1987) . Imagine expensing a plant during construction, such as the multi-million dollar Utah chip production plant which never opened in 1999 or 2000. The same effect may occur when intangible assets arising from research costs are expensed in the year they are incurred. The mandated expense treatment provides an incentive to spend a disproportionate share of R&D on projects that have a short-term rather than long-term return. Researching a new product frequently requires a 5 to 10 year investment (Biggadike, 1979) . Traditionally the product life cycle has been even longer. Thus research planning influenced by quarterly or annual reported earnings may adversely affect both individual companies as well as our national economy. When a capital asset such as R&D is expensed in the year incurred, reported income is distorted due to a lack of matching of expenditures with related revenue generation (Thomas, 1969) . Prior to 1974, financial reporting of R&D expenditures ran the gauntlet between full capitalization in the year incurred versus full expensing in the year incurred (SFAS No. 2, 1974) . The impact of tax policy on financial reporting no doubt influenced the passage and acceptance of SFAS No. 2. The use of a contra stockholders' equity account in which all R&D expenditures would be placed when incurred and then later amortized is a possible compromise solution; immediate write off for tax purposes need not be affected (Raby, 1967; Tax Foundation, 1990) . At the end of each year a fixed percent (such as 20%) of what is remaining in the equity account from prior years' expenditures would be charged to R&D expense for the current year. With this proposed contra stockholder account method, during periods of increasing R&D expenditures, current R&D expenses would be less than under the required expense-asincurred method. Thus, under the proposal, the current R&D expenditures would be expensed over their future revenue-producing period; but, during periods of decreasing R&D expenditures, current R&D expenses would be greater under the proposed method than in current practice. Again, R&D expenditures are more closely matched to their revenue-producing period. When there is no change in the total R&D expenditures from year to year, current R&D expenses would be the same under the proposal and the required expense-as-incurred method. Thus, R&D expenditures would be more closely matched to R&D revenue generated under the proposed contra stockholder equity account method under all budgeting situations. The proposal also encourages a shift from short-to long-term R&D under all three situations. (See Illustration of "Contra Stockholder Equity" Approach)
The use of a contra stockholders' equity approach is already required and used in accounting for the unrealized loss on long-term marketable securities, the translation gains and losses on foreign currency amounts, the net loss not recognized as pension expense and treasury stock transactions (SFAS No. 12, 1975; SFAS No. 52, 1981; SFAS No. 87, 1988 ).
In the current study members from the Financial Directors Network of the Industrial Research Institute, representing over 40 percent of the industrial R&D in the U.S., responded to a questionnaire survey. Greater than 50% of those receiving the questionnaire replied in a usable format. These respondents represent corporations, which account for over 20 percent of the corporate R&D spending in the U.S. The average annual R&D expenditures of these companies are 65% of average annual profits. When R&D expenditures are 65% of profits, it is easy to picture how, under current practice, R&D expenditures may be cut back to boost profit during a profit squeeze.
Results of Questionnaire
Questions asked referred to the use of such a contra stockholders' equity account and to what was the most appropriate financial disclosure of R&D expenditures in general. When asked the following question, "After enactment of this proposal, the current year's expenses would normally be unaffected by the current year's R&D expenditures. When current profits are unsatisfactory to higher management, in general, what effect (if any) would the proposed method have on current year R&D expenditures relative to the now required expense as incurred practice?" 48% indicated that they would increase their current year's R&D, 12% indicated a decrease, and 40% indicated no change. These results indicate that our present "expense as incurred rule" may well inhibit total R&D expenditures in the periods they are most badly needed. Also, some companies would be affected while many others would not. answered that R&D expenditures would be increased. The remaining 68% replied that there would be no effect. Once again, we are reminded that the proposed method may have a significant impact on increasing R&D expenditures.
Illustration of "Contra Stockholder Equity" Approach

When asked the following question, "After enactment of this proposal, what effect (if any) relative to present practice will there be in the amount of long-term R&D expenditures compared to short-term R&D expenditures?
Nearly one-half (44%) of the respondents indicated that there would be an increase in long-term compared to short-term R&D expenditures under the proposed method, while 56% indicated there would be no effect. United States industry has, for many years, been frequently criticized for emphasizing short-term returns at the expense of overall long-term benefit. It is significant that simply by changing the required method of financial reporting, nearly one-half of the respondents would spend less of their total R&D budget on short-term projects and more on longterm. It is apparent that required financial reporting is influencing corporate financial management to make decisions that conflict with sound R&D management and the long-term benefit of the company.
A pressing problem in R&D budgeting in many companies is annual fluctuation of R&D expenditures. This is certainly due, in part, to keeping short-term financial reported profits stable or positive. With this is mind, respondents were asked the following question: "After enactment of this proposal, what effect (if any) relative to present practice will there be in the annual fluctuations (if any) of R&D expenditures?" Over one-third (33%) of the respondents replied that there would be a decrease in annual fluctuations, 8% indicated an increase, while the remaining 56% believed there would be no effect. We are not suggesting there would not be annual fluctuations in R&D expenditures but rather that fluctuations should not be a result of financial reporting requirements which may pressure managers to decrease R&D at times when it is most badly needed.
Finally, answering the last questions, "Do you feel this contra stockholders' equity method of accounting for R&D may allow U.S. companies to compete more effectively in the international market?" 42% of the respondents answered yes, 54% no and 4% not sure. Presumably, the respondents answering "yes" did so because they felt that the proposed method would provide an incentive for more to be spent on R&D or a shift in R&D to longer term projects or both.
A separate part of the questionnaire listed four proposed methods of reporting research and development expenditures in published financial statements. After reading the four methods, respondents were asked to indicate on a scale, from 1-least appropriate, to 7-most appropriate how appropriate each method would be for their firm. The methods scored, respectively, as follows: the expense-as-incurred method in practice, an average of 5.6; the proposed contra stockholders' equity method, and average of 4; a capitalization and fixed write-off method, and average of 2.5; and a choice of either capitalization (shown as an asset) or charge to income as incurred, depending on estimates of future productiveness, an average of 2.6. It is noteworthy that the proposed contra stockholder method scored almost as high as the expense-as-incurred method use in practice. This is particularly so because the above numbers represent the averages for all respondents. 
